Green Collar CFO

02/06/2026

Happy Friday from your Green Collar CFO!

01/26/2026

01/09/2026

Hello and Happy Friday from your Green Collar CFO!

01/03/2026

Wealthy people don’t own valuable assets in their personal name.

Not real estate.
Not businesses.
Not equipment.
Not intellectual property.

Personally? They own almost nothing.

Instead, they control everything through structure.

A common setup looks like this:
→ A family trust owns a holding company
→ One LLC holds the real estate
→ Another LLC runs the operating business
→ A separate LLC owns equipment
→ An S-Corp manages and licenses IP

And this isn’t accidental. It’s strategic.

Lawsuit protection:
If one entity gets sued, only that entity is exposed. The real estate, equipment, and IP stay insulated.

Tax optimization:
Different assets get different tax treatment.
Real estate depreciates.
Equipment qualifies for bonus depreciation.
IP generates licensing income.
Structure creates options options reduce taxes.

Exit flexibility:
Want to sell the business but keep the building? No problem.
Want investors in operations but not assets? Easy.
Each piece stands alone.

Estate planning:
Ownership interests can be transferred through trusts without giving up control or triggering chaos later.

Most people wait until they’re “big enough” to do this right.

By then, they’ve already built equity in the wrong place and exposed everything to unnecessary risk.

Wealthy people do it the other way around.

They structure first.
Then they build.

If you personally own business assets or investment property, the issue isn’t income—it’s structure.

The wealthy separate everything.
They control it all.
And they don’t personally own any of it.

12/23/2025

I am writing to provide a clear, fact-checked summary regarding the potential rescheduling of cannabis from Schedule I to Schedule III.

Given the conflicting information circulating on social media, I want to ensure you have an accurate understanding of how this development may impact your business planning.

Important Clarification...
This is not a bill passed by Congress, but an administrative rescheduling process initiated by the Executive Branch and managed by the Department of Justice (DOJ) and the Drug Enforcement Administration (DEA). Current laws remains in effect until a final rule is issued and becomes effective.

Potential Improvements (Pros)

- End of 280E: If finalized, Internal Revenue Code §280E, which applies only to Schedule I and II substances, should no longer apply. This would allow for ordinary business deductions (e.g., rent, payroll, marketing) subject to standard tax rules.
- Reduced Federal Criminal Severity: Schedule III substances carry lower criminal penalties. While this does not legalize cannabis federally, it reduces overall federal exposure.
- Research and Medical Legitimacy: Schedule III status recognizes "accepted medical use" and reduces barriers to scientific research.

Limitations and Considerations (Cons)

- Federal Legalization: Cannabis remains a federally controlled substance. Interstate commerce remains prohibited, and state-legal programs are not yet recognized under federal law.
- Timeline: Current laws, including 280E, remain in place until the DEA issues a final rule with a specific effective date.
- Regulatory Compliance: While dispensaries are not expected to become pharmacies, Schedule III substances are subject to increased DEA and FDA oversight.
- Institutional Lag: Banking, insurance, and employment policies may not change immediately despite rescheduling.

Addressing Common Misconceptions

- State Program Protection: Schedule I status provided no legal protection; any practical protection has resulted from enforcement discretion and budget restrictions.
- Dispensary Closures: Claims that dispensaries must shut down or become pharmacies are incorrect; Schedule III substances use various regulated distribution models.
- Pharmaceutical Takeover: While pharmaceutical companies have long held cannabinoid patents, rescheduling does not grant them exclusivity or eliminate state markets.

Practical Guidance

- Continue to plan conservatively until a final effective date is established.
- Do not assume immediate 280E tax relief.
- Maintain strict state-level compliance and clean documentation (COGS, inventory, payroll, and intercompany activity).

Sources:

1. U.S. Department of Justice, Proposed Rule: Rescheduling of Ma*****na (2024)
2. Drug Enforcement Administration, Controlled Substances Act Scheduling Framework
3. Internal Revenue Code §280E
4. U.S. Department of Health and Human Services, Scientific Review Supporting Schedule III Recommendation
5. Congressional Research Service, Federal Cannabis Law and Policy Overview

I will continue to monitor these developments closely and will advise you immediately upon the publication of a final rule.

Please feel free to reach out if you have any questions.

[email protected]

12/20/2025

Hello to all,

I am writing to provide a clear, fact-checked summary regarding the potential rescheduling of cannabis from Schedule I to Schedule III.

Given the conflicting information circulating on social media, I want to ensure you have an accurate understanding of how this development may impact your business planning.

Important Clarification...
This is not a bill passed by Congress, but an administrative rescheduling process initiated by the Executive Branch and managed by the Department of Justice (DOJ) and the Drug Enforcement Administration (DEA). Current laws remains in effect until a final rule is issued and becomes effective.

Potential Improvements (Pros)

- End of 280E: If finalized, Internal Revenue Code §280E, which applies only to Schedule I and II substances, should no longer apply. This would allow for ordinary business deductions (e.g., rent, payroll, marketing) subject to standard tax rules.
- Reduced Federal Criminal Severity: Schedule III substances carry lower criminal penalties. While this does not legalize cannabis federally, it reduces overall federal exposure.
- Research and Medical Legitimacy: Schedule III status recognizes "accepted medical use" and reduces barriers to scientific research.

Limitations and Considerations (Cons)

- Federal Legalization: Cannabis remains a federally controlled substance. Interstate commerce remains prohibited, and state-legal programs are not yet recognized under federal law.
- Timeline: Current laws, including 280E, remain in place until the DEA issues a final rule with a specific effective date.
- Regulatory Compliance: While dispensaries are not expected to become pharmacies, Schedule III substances are subject to increased DEA and FDA oversight.
- Institutional Lag: Banking, insurance, and employment policies may not change immediately despite rescheduling.

Addressing Common Misconceptions

- State Program Protection: Schedule I status provided no legal protection; any practical protection has resulted from enforcement discretion and budget restrictions.
- Dispensary Closures: Claims that dispensaries must shut down or become pharmacies are incorrect; Schedule III substances use various regulated distribution models.
- Pharmaceutical Takeover: While pharmaceutical companies have long held cannabinoid patents, rescheduling does not grant them exclusivity or eliminate state markets.

Practical Guidance

- Continue to plan conservatively until a final effective date is established.
- Do not assume immediate 280E tax relief.
- Maintain strict state-level compliance and clean documentation (COGS, inventory, payroll, and intercompany activity).

Sources:

1. U.S. Department of Justice, Proposed Rule: Rescheduling of Ma*****na (2024)
2. Drug Enforcement Administration, Controlled Substances Act Scheduling Framework
3. Internal Revenue Code §280E
4. U.S. Department of Health and Human Services, Scientific Review Supporting Schedule III Recommendation
5. Congressional Research Service, Federal Cannabis Law and Policy Overview

I will continue to monitor these developments closely and will advise you immediately upon the publication of a final rule.

Please feel free to reach out if you have any questions.

[email protected]

12/14/2025

Happy Hollidays from Green Collar CFO